Orient Europharma Co Ltd (TWO:4120) — Market Cap & Net Worth
Market Cap & Net Worth: Orient Europharma Co Ltd (4120)
Orient Europharma Co Ltd (TWO:4120) has a market capitalization of $14.88K (NT$472.41K) as of August 3, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #31641 globally and #1592 in its home market, demonstrating a 2.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orient Europharma Co Ltd's stock price NT$47.35 by its total outstanding shares 9977 (9.98K). See Orient Europharma Co Ltd capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Orient Europharma Co Ltd Market Cap History: 2015 to 2026
Orient Europharma Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $14.69K to $14.88K (1.12% CAGR).
Orient Europharma Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orient Europharma Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Orient Europharma Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $14.69K | $4.91 Billion | $223.16 Million | 0.00x | 0.00x |
| 2016 | $15.77K | $5.23 Billion | $469.61 Million | 0.00x | 0.00x |
| 2017 | $20.63K | $5.23 Billion | $458.73 Million | 0.00x | 0.00x |
| 2018 | $14.12K | $5.51 Billion | $246.74 Million | 0.00x | 0.00x |
| 2019 | $15.52K | $6.09 Billion | $247.66 Million | 0.00x | 0.00x |
| 2020 | $13.91K | $5.38 Billion | $199.30 Million | 0.00x | 0.00x |
| 2021 | $10.92K | $4.77 Billion | $120.17 Million | 0.00x | 0.00x |
| 2022 | $11.15K | $4.73 Billion | -$310.80 Million | 0.00x | N/A |
| 2023 | $11.98K | $4.59 Billion | $143.94 Million | 0.00x | 0.00x |
| 2024 | $15.15K | $4.39 Billion | -$283.93 Million | 0.00x | N/A |
Competitor Companies of 4120 by Market Capitalization
Companies near Orient Europharma Co Ltd in the global market cap rankings as of August 3, 2026.
Key companies related to Orient Europharma Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Orient Europharma Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Orient Europharma Co Ltd's market cap moved from $14.69K to $ 14.88K, with a yearly change of 1.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$14.88K | +5.69% |
| 2025 | NT$14.08K | -7.05% |
| 2024 | NT$15.15K | +26.44% |
| 2023 | NT$11.98K | +7.46% |
| 2022 | NT$11.15K | +2.13% |
| 2021 | NT$10.92K | -21.52% |
| 2020 | NT$13.91K | -10.34% |
| 2019 | NT$15.52K | +9.88% |
| 2018 | NT$14.12K | -31.54% |
| 2017 | NT$20.63K | +30.76% |
| 2016 | NT$15.77K | +7.38% |
| 2015 | NT$14.69K | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Orient Europharma Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.88K USD |
| MoneyControl | $14.88K USD |
| MarketWatch | $14.88K USD |
| marketcap.company | $14.88K USD |
| Reuters | $14.88K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more